Amniotics AB (publ) announced that it has received a non-diluting grant of SEK 4.8 million from Sweden's Innovation Agency, Vinnova, together with Professor Sandra Lindstedt at Skåne University Hospital. The grant will be used to demonstrate proof of concept of using Amniotics stem cell therapy to repair damaged discarded donor lungs for transplantation and for reducing the incidence of unwanted side-effects after lung transplantations. In the research project funded by Vinnova, Amniotics and Professor Sandra Lindstedt at Skåne University Hospital will work together to build a platform to develop and test a new biological therapy using amniotic fluid-derived stem cells (PulmoStemTM).

The focus will be on applying stem cells to regenerate donor lungs making them suitable for transplantation, as well as studies into treatment post transplantation to increase engraftment of the transplants and reduce rates of Primary Graft Dysfunction (PGD). These studies will allow for roll-over into clinical trial.